vs
HAEMONETICS CORP（HAE）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是BRC Group Holdings, Inc.的1.8倍（$339.0M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 13.2%，领先34.7%），HAEMONETICS CORP同比增速更快（-2.7% vs -21.9%），过去两年HAEMONETICS CORP的营收复合增速更高（0.4% vs -15.4%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
HAE vs RILY — 直观对比
营收规模更大
HAE
是对方的1.8倍
$188.3M
营收增速更快
HAE
高出19.1%
-21.9%
净利率更高
RILY
高出34.7%
13.2%
两年增速更快
HAE
近两年复合增速
-15.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $188.3M |
| 净利润 | $44.7M | $90.3M |
| 毛利率 | 59.7% | 79.5% |
| 营业利润率 | 19.9% | 32.3% |
| 净利率 | 13.2% | 47.9% |
| 营收同比 | -2.7% | -21.9% |
| 净利润同比 | 19.3% | 1710.8% |
| 每股收益（稀释后） | $0.95 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAERILY
| Q4 25 | $339.0M | $188.3M | ||
| Q3 25 | $327.3M | $215.3M | ||
| Q2 25 | $321.4M | $188.2M | ||
| Q1 25 | $330.6M | $197.2M | ||
| Q4 24 | $348.5M | $241.0M | ||
| Q3 24 | $345.5M | $225.5M | ||
| Q2 24 | $336.2M | $256.0M | ||
| Q1 24 | — | $263.4M |
净利润HAERILY
| Q4 25 | $44.7M | $90.3M | ||
| Q3 25 | $38.7M | $91.1M | ||
| Q2 25 | $34.0M | $139.5M | ||
| Q1 25 | $58.0M | $-10.0M | ||
| Q4 24 | $37.5M | $-5.6M | ||
| Q3 24 | $33.8M | $-284.4M | ||
| Q2 24 | $38.4M | $-433.6M | ||
| Q1 24 | — | $-49.2M |
毛利率HAERILY
| Q4 25 | 59.7% | 79.5% | ||
| Q3 25 | 59.5% | 83.7% | ||
| Q2 25 | 59.8% | 81.3% | ||
| Q1 25 | 58.4% | 81.4% | ||
| Q4 24 | 55.5% | 79.8% | ||
| Q3 24 | 54.2% | 82.1% | ||
| Q2 24 | 52.0% | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率HAERILY
| Q4 25 | 19.9% | 32.3% | ||
| Q3 25 | 17.9% | 30.4% | ||
| Q2 25 | 16.8% | 5.7% | ||
| Q1 25 | 21.6% | -31.2% | ||
| Q4 24 | 16.9% | -69.2% | ||
| Q3 24 | 15.0% | -36.4% | ||
| Q2 24 | 11.8% | -90.8% | ||
| Q1 24 | — | -6.1% |
净利率HAERILY
| Q4 25 | 13.2% | 47.9% | ||
| Q3 25 | 11.8% | 42.3% | ||
| Q2 25 | 10.6% | 74.1% | ||
| Q1 25 | 17.5% | -5.1% | ||
| Q4 24 | 10.8% | -2.3% | ||
| Q3 24 | 9.8% | -126.1% | ||
| Q2 24 | 11.4% | -169.4% | ||
| Q1 24 | — | -18.7% |
每股收益（稀释后）HAERILY
| Q4 25 | $0.95 | $2.78 | ||
| Q3 25 | $0.81 | $2.91 | ||
| Q2 25 | $0.70 | $4.50 | ||
| Q1 25 | $1.17 | $-0.39 | ||
| Q4 24 | $0.74 | $-0.01 | ||
| Q3 24 | $0.66 | $-9.39 | ||
| Q2 24 | $0.74 | $-14.35 | ||
| Q1 24 | — | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $226.6M |
| 总债务越低越好 | $1.2B | $1.4B |
| 股东权益账面价值 | $911.5M | $-171.5M |
| 总资产 | $2.5B | $1.7B |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资HAERILY
| Q4 25 | $363.4M | $226.6M | ||
| Q3 25 | $296.4M | $184.2M | ||
| Q2 25 | $292.9M | $267.4M | ||
| Q1 25 | $306.8M | $138.3M | ||
| Q4 24 | $320.8M | $146.9M | ||
| Q3 24 | $299.3M | $159.2M | ||
| Q2 24 | $344.4M | $236.9M | ||
| Q1 24 | — | $190.7M |
总债务HAERILY
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HAERILY
| Q4 25 | $911.5M | $-171.5M | ||
| Q3 25 | $849.2M | $-260.5M | ||
| Q2 25 | $882.3M | $-351.7M | ||
| Q1 25 | $820.8M | $-496.8M | ||
| Q4 24 | $906.9M | $-488.2M | ||
| Q3 24 | $878.9M | $-497.6M | ||
| Q2 24 | $905.4M | $-218.3M | ||
| Q1 24 | — | $228.4M |
总资产HAERILY
| Q4 25 | $2.5B | $1.7B | ||
| Q3 25 | $2.4B | $1.7B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.5B | $1.5B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | — | $5.0B |
负债/权益比HAERILY
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $87.2M | — |
| 自由现金流率自由现金流/营收 | 25.7% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | 2.09× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $308.1M | — |
8季度趋势，按日历期对齐
经营现金流HAERILY
| Q4 25 | $93.6M | $26.2M | ||
| Q3 25 | $111.3M | $-60.6M | ||
| Q2 25 | $17.4M | $-25.6M | ||
| Q1 25 | $116.6M | $184.0K | ||
| Q4 24 | $43.8M | $-2.7M | ||
| Q3 24 | $48.8M | $19.5M | ||
| Q2 24 | $-27.4M | $111.5M | ||
| Q1 24 | — | $135.4M |
自由现金流HAERILY
| Q4 25 | $87.2M | — | ||
| Q3 25 | $106.3M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $35.2M | — | ||
| Q3 24 | $39.4M | — | ||
| Q2 24 | $-33.1M | — | ||
| Q1 24 | — | — |
自由现金流率HAERILY
| Q4 25 | 25.7% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 30.5% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -9.8% | — | ||
| Q1 24 | — | — |
资本支出强度HAERILY
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | — | — |
现金转化率HAERILY
| Q4 25 | 2.09× | 0.29× | ||
| Q3 25 | 2.88× | -0.66× | ||
| Q2 25 | 0.51× | -0.18× | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
